Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Other Events

ME Staff 8-k
-
0

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Other Events
Item 8.01 Other Events.

On December 15, 2017, Aclaris Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved ESKATATM (hydrogen peroxide) topical solution, 40% (w/w), for the treatment of raised seborrheic keratoses.A copy of the press release is filed herewith as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


Aclaris Therapeutics, Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 Ex 99.1   Exhibit 99.1   Aclaris Therapeutics Receives FDA Approval for ESKATA™  (Hydrogen Peroxide) Topical Solution,…
To view the full exhibit click here

About Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.